Biogen | BIIB - Current Liabilities


Biogen reported $3B in Current Liabilities for its fiscal quarter ending in March of 2026.





Current Liabilities Change Date
AbbVie USD 43.29B 3.9B Dec/2025
Acadia Pharmaceuticals USD 277.11M 79.47M Dec/2025
ALKERMES USD 599.5M 56.06M Mar/2026
Amgen USD 24.96B 534M Mar/2026
Bayer EUR 32.58B 3.63B Dec/2025
Biogen USD 3B 350.5M Mar/2026
BioMarin Pharmaceutical USD 793.15M 34.12M Mar/2026
Bristol-Myers Squibb USD 19.16B 4.26B Mar/2026
Eli Lilly USD 36.63B 1.41B Mar/2026
Esperion Therapeutics USD 300.81M 58.22M Dec/2025
Gilead Sciences USD 11.81B 485M Dec/2025
Incyte USD 1.49B 25.52M Mar/2026
Merck USD 26.94B 1.38B Mar/2026
Moderna USD 2.4B 408M Mar/2026
Neurocrine Biosciences USD 831.7M 88.3M Mar/2026
Novartis USD 31.37B 4.1B Mar/2026
Pfizer USD 34.35B 2.64B Mar/2026
PTC Therapeutics USD 968.43M 102.18M Dec/2025
Puma Biotechnology USD 82.73M 3.63M Sep/2025
Regeneron Pharmaceuticals USD 5.11B 739.3M Mar/2026
Sangamo BioSciences USD 47.66M 1.9M Jun/2025
Sanofi EUR 30.01B 1.66B Mar/2026
Sanofi EUR 28.35B 9.32B Dec/2025
Sarepta Therapeutics USD 1.1B 173.86M Dec/2025
Teva Pharmaceutical Industries USD 13.53B 76M Mar/2026
Ultragenyx Pharmaceutical USD 384M 43.98M Dec/2025
United Therapeutics USD 560.6M 14.3M Dec/2025
Vertex Pharmaceuticals USD 3.88B 19.4M Mar/2026